MET and ovarian carcinoma: Although the contributions of MET and EPHB4 to ovarian cancer remain relatively unclear as compared with the EGFR and VEGFR families, recent studies have observed that these two RTKs are regularly overexpressed in tumors from patients with ovarian cancers51, 52.